多中心,国际子宫内膜癌联合会的亮点
Luigi De Vitis1, Anna Giudici2, Vincenzo Tarantino3
1Mayo Clinic, Department of Obstetrics and Gynecology, Rochester, MN, USA.
概括
领先的妇科瘤学专家召开会议,讨论子宫内膜癌治疗的进展,重点关注分子测试,先进的治疗方法和病理学. 该联盟的目标是通过合作研究和临床创新来改善患者的治疗结果.
科学领域:
- 妇科瘤学 妇科瘤学
- 癌症研究 癌症研究
- 病理学 病理学 病理学
背景情况:
- 子宫内膜癌的诊断和治疗需要不断更新.
- 国际合作对于促进妇科瘤学的发展至关重要.
- 专家们召开会议,以解决子宫内膜癌的关键挑战.
研究的目的:
- 探索子宫内膜癌理解,诊断和治疗的最新进展.
- 确定研究重点,并制定针对子宫内膜癌的可行的策略.
- 为未来的研究和临床创新促进跨学科的合作.
主要方法:
- 一个多中心,国际联盟举行.
- 讨论的重点是分子测试,疾病分期,晚期/复发性疾病治疗,节育管理和病理挑战.
- 专门的工作组会议促进了深入的交流.
主要成果:
- 关键话题包括分子测试更新,疾病阶段和新兴治疗策略.
- 检查了关键的病理挑战,如淋巴血管空间入侵评估.
- 会议概述了未来在子宫内膜癌方面的进展路线图.
结论:
- 该联盟确定了对子宫内膜癌的研究优先事项和可行的策略.
- 建立了跨学科的合作,作为未来研究的基础.
- 这次会议的目的是推动临床创新,并改善患者在子宫内膜癌的治疗结果.
更多相关视频
09:48An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
Published on: September 12, 2019
8.0K
05:52Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
11.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...